Loading...
In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance
BACKGROUND: Raloxifene hydrochloride (RLX) is approved by the US Food and Drug Administration for the treatment and prevention of osteoporosis, in addition to reducing the risk of breast cancer in postmenopausal women. RLX has the disadvantages of low aqueous solubility, extensive presystemic intest...
Saved in:
| Published in: | Int J Nanomedicine |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Dove Medical Press
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6188068/ https://ncbi.nlm.nih.gov/pubmed/30349253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S181587 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|